ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 170 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,217,703 | -51.8% | 198,541 | -7.6% | 0.00% | -100.0% |
| Q2 2023 | $4,599,245 | -67.4% | 214,918 | -38.4% | 0.00% | -66.7% |
| Q1 2023 | $14,103,733 | +19.0% | 348,757 | +36.9% | 0.00% | 0.0% |
| Q4 2022 | $11,851,715 | +41.7% | 254,766 | +58.0% | 0.00% | +200.0% |
| Q3 2022 | $8,365,000 | +155.0% | 161,262 | +132.4% | 0.00% | 0.0% |
| Q2 2022 | $3,281,000 | +7.5% | 69,400 | +61.9% | 0.00% | – |
| Q1 2022 | $3,051,000 | +3.8% | 42,872 | +9.1% | 0.00% | – |
| Q4 2021 | $2,939,000 | +4.5% | 39,301 | -20.6% | 0.00% | -100.0% |
| Q3 2021 | $2,812,000 | -56.3% | 49,494 | -66.1% | 0.00% | -50.0% |
| Q2 2021 | $6,431,000 | -21.5% | 146,147 | -12.0% | 0.00% | 0.0% |
| Q1 2021 | $8,189,000 | +51.2% | 166,039 | +29.1% | 0.00% | +100.0% |
| Q4 2020 | $5,415,000 | +124.1% | 128,629 | +143.7% | 0.00% | 0.0% |
| Q3 2020 | $2,416,000 | +2.4% | 52,789 | +12.4% | 0.00% | 0.0% |
| Q2 2020 | $2,359,000 | -76.5% | 46,985 | -76.0% | 0.00% | -80.0% |
| Q1 2020 | $10,049,000 | +30.3% | 195,393 | +56.5% | 0.01% | +25.0% |
| Q4 2019 | $7,711,000 | +22.0% | 124,814 | +18.7% | 0.00% | +33.3% |
| Q3 2019 | $6,319,000 | -76.2% | 105,163 | -66.6% | 0.00% | -75.0% |
| Q2 2019 | $26,590,000 | +2.2% | 315,107 | +15.7% | 0.01% | -14.3% |
| Q1 2019 | $26,016,000 | +1091.2% | 272,372 | +783.4% | 0.01% | – |
| Q4 2018 | $2,184,000 | -36.6% | 30,831 | -23.5% | 0.00% | -100.0% |
| Q3 2018 | $3,445,000 | -30.4% | 40,317 | -5.6% | 0.00% | -50.0% |
| Q2 2018 | $4,948,000 | +129.9% | 42,689 | +60.5% | 0.00% | +100.0% |
| Q1 2018 | $2,152,000 | +294.1% | 26,594 | +186.0% | 0.00% | – |
| Q4 2017 | $546,000 | -33.3% | 9,300 | -46.9% | 0.00% | – |
| Q3 2017 | $819,000 | +32.5% | 17,510 | +1.8% | 0.00% | – |
| Q2 2017 | $618,000 | -44.8% | 17,200 | -52.7% | 0.00% | -100.0% |
| Q1 2017 | $1,120,000 | +389.1% | 36,363 | +475.4% | 0.00% | – |
| Q3 2015 | $229,000 | -73.9% | 6,320 | -77.9% | 0.00% | -100.0% |
| Q1 2015 | $877,000 | -35.9% | 28,639 | +6.5% | 0.00% | 0.0% |
| Q4 2014 | $1,368,000 | -25.7% | 26,896 | -42.2% | 0.00% | -50.0% |
| Q3 2014 | $1,841,000 | +492.0% | 46,554 | +544.7% | 0.00% | – |
| Q2 2014 | $311,000 | +25.4% | 7,221 | +16.3% | 0.00% | – |
| Q1 2014 | $248,000 | -10.1% | 6,210 | -38.6% | 0.00% | – |
| Q4 2013 | $276,000 | – | 10,113 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |